<DOC>
	<DOCNO>NCT02497300</DOCNO>
	<brief_summary>Vascular endothelial dysfunction increase cardiovascular ( CV ) risk contributes progression chronic kidney disease ( CKD ) . Mineralocorticoid receptor ( MR ) antagonists show improve endothelial function , well decrease CV mortality proteinuria . The specific biochemical pathway produce pharmacological effect MR antagonist , however , poorly understood . This study investigate effect MR antagonism endothelial function patient moderate ( stage III ) CKD use randomize , control trial . Three specific aim propose : Aim 1 : To determine spironolactone improve endothelial function compare amiloride patient stage III CKD ; Aim 2 : To determine oxidative stress associate change endothelial function spironolactone compare amiloride patient stage III CKD ; Aim 3 : To determine endothelial dysfunction contributes albuminuria patient stage III CKD . The clinical relevance improve understand mechanisms kidney function decline CKD order develop intervention delay prevent dialysis , would translate alleviate patient suffering , caregiver burden , health care cost .</brief_summary>
	<brief_title>Vascular Effects Mineralocorticoid Receptor Antagonism Kidney Disease</brief_title>
	<detailed_description>Study participant proteinuric , stage III CKD randomly assign double-masked fashion spironolactone 25mg daily amiloride 5 mg daily 6 week cross alternate study medication 1 month wash-out period . Vascular function assess baseline end 6 week treatment period : 1 ) ultrasound guide flow-mediated dilation ( FMD ) brachial artery , 2 ) impedence cardiography , 3 ) pulse-wave velocity , 4 ) 24 hour ambulatory blood pressure monitoring , 5 ) serum urine biomarkers . Participants undergo total 7 visit 16-18 week ; 3 7 visit involve vascular function test . A study visit vascular function test perform begin 0800 morning start vital sign assessment include height , weight , body fat percent , leave arm automate BP measurement follow confirmation fasting status brief past medical history . Each participant lie supine 10 minute preparation vascular function test . Following pulse wave velocity , impedence cardiography , FMD measurement , participant his/her blood urine collect laboratory testing . Laboratory test include ~20 mL blood plasma serum test . Participants return 24 hour urine sample 24 hour ambulatory monitor place . This entire visit expect take 2 hour . Study visit vascular function test perform ( e.g. , screen visit , visit 2 , visit 4 , visit 5 ; last 30 minute involve medication assessment , vital sign check , blood collection serum potassium ( ~4 mL blood ) . All study medication prepare University Alabama ( UAB ) Research Pharmacy match capsule place pill bottle label `` A '' `` B '' . The order medication dispense follow simple randomization use priori randomization list prepare research pharmacy . All study personnel participant interaction mask order study medication .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Amiloride</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>Adults ( 1865 year age ) CKD ( eGFR 2560 mL/min/1.73m2 ) urine ACR &gt; 30 mg/g CKD ( eGFR &gt; 60 mL/min/1.73m2 ) urine ACR ≥ 300 mg/g Severe hypertension ( HTN ) ( office BP ≥ 160/100 mm Hg ) Hypotension ( office BP &lt; 110/70 mm Hg ) Serum potassium &gt; 5 milliequivalent/L History arrhythmia , include atrial fibrillation Pregnant breast feed woman Diabetes mellitus ( DM ) type 1 Diabetes mellitus type 2 glycosylated hemoglobin ≥ 6.5 % Dementia cognitive impairment prohibit consent History ischemic stroke , unstable angina , myocardial infarction within past 6 month Allergy intolerance spironolactone amiloride Use MR antagonist epithelial sodium channel block medication within last month Known primary aldosteronism renal artery stenosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Mineralocorticoid Receptor Antagonists</keyword>
	<keyword>Mineralocorticoid Effects</keyword>
</DOC>